Showing 4521-4530 of 20466 results for "".
- Case Report Highlights Zero-CO₂ Endoscopic TDAP Flap for Breast Reconstruction Salvagehttps://reachmd.com/news/case-report-highlights-zero-co-endoscopic-tdap-flap-for-breast-reconstruction-salvage/2487670/A computed tomographic angiography (CTA)-guided endoscopic thoracodorsal artery perforator (TDAP) flap harvested without carbon dioxide (CO₂) insufflation successfully salvaged breast reconstruction following complete deep inferior epigastric perforator (DIEP) flap loss in a recently published ca
- Platelet-Rich Plasma vs Corticosteroids and NSAIDs in Knee Osteoarthritishttps://reachmd.com/news/platelet-rich-plasma-corticosteroids-nsaids-knee-osteoarthritis/2487664/Key Takeaways Platelet-rich plasma was associated with better pain scores and WOMAC outcomes than corticosteroid injection and oral NSAID treatment at follow-up. Opioid use was lower with platelet-rich plasma at 3 months than with both control groups a
- n-Butyl Cyanoacrylate MMA Embolization in cSDH: Randomized Trialhttps://reachmd.com/news/n-butyl-cyanoacrylate-mma-embolization-csdh/2487663/Key Takeaways The primary effectiveness endpoint was reported less often with embolization plus standard care than with standard care alone. Adverse events through 6 months were not reported to increase significantly with embolization plus standard car
- Combined Lower Blepharoplasty and PDO Thread Lift Shows Early Promise in Case Serieshttps://reachmd.com/news/combined-lower-blepharoplasty-and-pdo-thread-lift-shows-early-promise-in-case-series/2487655/A combined transcutaneous lower blepharoplasty and multi-directional polydioxanone (PDO) thread midface lift performed through a shared subciliary incision demonstrated favorable early aesthetic outcomes with no reported major complications in a prospective consecutive case series published in
- Embedded Primary Care in Adult Sickle Cell Teamshttps://reachmd.com/news/embedded-primary-care-in-adult-sickle-cell-teams/2487650/Key Takeaways The embedded model was associated with higher odds of several general preventive and sickle cell-specific care measures. Among patients who saw the embedded clinician, annual outpatient visits increased from 2.7 to 4.2 per year.
- FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsAhttps://reachmd.com/news/fda-expands-skyrizi-approval-to-include-children-with-plaque-psoriasis-and-psoriatic-arthritis/2487657/The FDA has expanded the indication for SKYRIZI® (risankizumab-rzaa) to include children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to an announcement from AbbVie.
- AI Chest X-Ray Prioritization Did Not Shorten Lung Cancer Pathwayhttps://reachmd.com/news/ai-chest-x-ray-prioritization-did-not-shorten-lung-cancer-pathway/2487646/Key Takeaways Immediate AI prioritization was not associated with shorter time to CT or lung cancer diagnosis. Secondary pathway outcomes were also similar, including urgent referral timing, treatment timing, stage at diagnosis, and lung cancer inciden
- Nociception-Guided Opioids In Laparoscopic Endometriosis Surgeryhttps://reachmd.com/news/nociception-guided-opioids-in-laparoscopic-endometriosis-surgery/2487647/Key Takeaways Perioperative opioid consumption was similar between NOL-guided analgesia and standard care within the standardized multimodal protocol. Postoperative pain scores were comparable at all reported time points, and no improvement in early po
- Radiofrequency Microneedling Shows Promise for Periorbital Skin Rejuvenationhttps://reachmd.com/news/radiofrequency-microneedling-shows-promise-for-periorbital-skin-rejuvenation/2487641/Radiofrequency microneedling (RFMN) demonstrated favorable safety and modest clinical improvements in periorbital skin rejuvenation in a prospective, evaluator-blinded clinical study published in the Journal of Cosmetic and Laser Therapy. Prospective Study Evaluates RFMN f
- Oncologist Preferences in First-Line Alk-Positive Metastatic NSCLChttps://reachmd.com/news/oncologist-preferences-in-first-line-alk-positive-metastatic-nsclc/2487572/Key Takeaways U.S. oncologists were asked to weigh several attributes of first-line ALK-targeted therapy in metastatic ALK-positive NSCLC. The choice-task attributes included efficacy, intracranial activity, safety, dosing convenience, and cost or cove